Palivizumab

Authors:

Abstract
In two double-blind, placebo-controlled trials, intramuscular palivizumab 15 mg/kg every 30 days for 5 months significantly reduced RSV-related hospitalizations by 55% in 1502 infants with prematurity and/or bronchopulmonary dysplasia/chronic lung disease (BPD/CLD) and by 45% in 1287 infants with hemodynamically significant congenital heart disease (HSCHD). Reductions were statistically significant versus placebo in infants with BPD/CLD, with all degrees of prematurity, and with acyanotic/other heart disease. Palivizumab was generally well tolerated, with ≤1.9% of recipients discontinuing treatment for tolerability reasons. In placebo-controlled trials, the most common potentially drug-related adverse events were fever, nervousness, injection-site reactions, and diarrhea. Drug-related events occurred in 7.2–11% of palivizumab recipients in controlled trials (vs 6.9–10% with placebo) and 0–7.9% in open-label trials. Very few serious potentially drug-related adverse events occurred in clinical trials; four occurred in 2 of 285 patients in one open-label trial. No significant anti-palivizumab antibodies developed during palivizumab use. Palivizumab trough serum concentrations were below the recommended 40 μg/mL in about 33% and up to 14% of children prior to their second and third palivizumab injections. In pharmacoeconomic studies, the cost of palivizumab per hospitalization averted was generally lowest in the highest-risk infants. Drug cost was generally the most influential factor in sensitivity analyses. In conclusion, prophylaxis with palivizumab significantly reduces the incidence of RSV-related hospitalization relative to placebo and is generally well tolerated in high-risk infants aged in vitro studies, palivizumab bound to and neutralized all respiratory syncytial virus (RSV) isolates tested and was more active against RSV than RSV intravenous immune globulin (RSV-IGIV). In vivo, a 99% reduction in RSV types A and B titers occurred in cotton rats at palivizumab serum concentrations of ≤30 μg/mL. Capsaicin-induced airway extravasation, potentiated by RSV infection, was significantly reduced in cotton rats treated with palivizumab either before or after intranasal RSV infection and before endotracheal infection. RSV-IGIV was effective before, but not after, intranasal RSV infection. Mean nasal RSV loads in infants aged min) of min 49.2–50.54 μg/mL), and up to 14% after their second (mean Cmin 69.4–76.8 μg/mL). In very premature neonates, 68% had a Cmin of min 32.2 μg/mL). Cmin values were similar in infants’first and second palivizumab seasons. Mean Cmin in infants aged ≤24 months with hemodynamically significant congenital heart disease (HSCHD) was 55.5 μg/mL after the first injection of palivizumab 15 mg/kg, with 7.9% of infants having a Cmin <30 μg/mL. The mean serum elimination half-life of palivizumab is 20 days in infants. Intramuscular palivizumab 15 mg/kg at 30-day intervals over 5 months during peak RSV season reduced the incidence of RSV-related hospitalization by 55%, from 10.6% to 4.8%, in a randomized, double-blind, placebo-controlled trial in 1502 high-risk, premature infants (the IMpact-RSV study). Infants were born at a gestational age of ≤35 weeks and aged ≤6 months or aged ≤24 months with active bronchopulmonary dysplasia/chronic lung disease (BPD/CLD). Reductions were significant in infants with gestational ages of 32 weeks, and bulk purchasing or lot preparation and dispensing of palivizumab. Palivizumab is indicated in the US for the prevention of serious lower respiratory tract infections in infants at high risk of RSV disease. In the EU it is indicated in infants aged <6 months at the start of the RSV season who were born at ≤35 weeks gestation and infants aged <2 years who have required treatment for BPD/CLD within 6 months of the RSV season, or have hemodynamically significant congenital heart disease. The recommended palivizumab dosage is 15 mg/kg administered intramuscularly each month from just before onset, through to the completion of, the RSV season, with the course continuing even if infants develop an RSV infection. The response to vaccines is not affected by palivizumab, and the need for supplemental doses of routine childhood vaccinations is not supported by data. No studies on the use of palivizumab in the treatment of established RSV disease have been undertaken.

This publication has 64 references indexed in Scilit: